The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

As members of the 118th Congress returned to Washington this week, everyone is focused on raising the nation’s debt limit, especially following Treasury Secretary Jane Yellen’s announcement that her agency would begin taking extraordinary measures to prevent the government from triggering a default. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Lisa M. Coussens, PhD
President, American Association for Cancer Research; Deputy director for basic & translational research, Knight Cancer Institute; Chair, Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Christian Hinrichs, of Rutgers Cancer Institute & RWJBarnabas Health, receives V Foundation for Cancer Research award

Christian Hinrichs, co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence and chief of the Section of Cancer Immunotherapy, RWJBarnabas Health, has been awarded a four-year, $800,000 translational research grant from the V Foundation for Cancer Research to develop next-generation immunotherapies for cancers caused by human papillomavirus. 

California state-funded institute scraps selection process that put cancer projects at a disadvantage
Cancer researchers are resubmitting applications to the California Institute for Regenerative Medicine

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.
By Sara Willa Ernst
Byline
Lisa M. Coussens, PhD
President, American Association for Cancer Research; Deputy director for basic & translational research, Knight Cancer Institute; Chair, Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account